Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

Q: What does this research mean for the field?

The monoamine oxidase B inhibitor selegiline reduces 18F-THK5351 uptake in the human brain, which impacts the interpretation of F-THK5351 PET scans. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Kok Pin Ng; Tharick A. Pascoal; Sulantha Mathotaarachchi; Joseph Therriault; Min Su Kang; Monica Shin; Marie-Christine Guiot; Qi Guo; Ryuichi Harada; Robert A. Comley; Gassan Massarweh; Jean-Paul Soucy; Nobuyuki Okamura; Serge Gauthier; Pedro Rosa‐Neto

doi:10.1186/s13195-017-0253-y

March 30, 2017Alzheimer s Research & TherapyOpen Access

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

BACKGROUND: F-THK5351 brain uptake using PET and autoradiography. METHODS: F-THK5351 competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline. RESULTS: F-THK5351 uptake. CONCLUSIONS: F-THK5351 scans using reference region methods.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ng et al. (2017) studied this question.

synapsesocial.com/papers/6a0775ce5589773960845644 https://doi.org/10.1186/s13195-017-0253-y

View Full Paper

Ask AI

Bookmark

Share

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

Ask about this paper

Abstract

Discussion

Cite This Study

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading